Anemia, Lung Cancer, Non-Small-Cell Lung Carcinoma
Conditions
Keywords
Quality of Life, Blood transfusion
Brief summary
The general objective of this study is to improve the Quality of Life (QoL) of selected patients with advanced carcinoma of the lung. The specific objective is to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and underlying anemia of malignancy.
Interventions
DRUGEpoetin Alfa
Sponsors
Ortho Biotech, Inc.
Ontario Clinical Oncology Group (OCOG)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed non-small cell lung cancer (squamous cell, large cell, adenocarcinoma, or some combination of these), with clinical or pathological stage III or IV, or recurrent disease; and 2. Hemoglobin level at or below 120 g/L; and 3. At least 18 years of age;
Exclusion criteria
1. Systemic platinum-based chemotherapy for lung cancer during the previous two months or planned platinum-based chemotherapy within the next three months; 2. Patients previously treated with high dose thoracic radiation (\>10 fractions), or surgery, without objective evidence of disease recurrence; 3. Planned high dose thoracic radiation therapy (\>10 fractions); 4. A clinically active malignancy, other than the underlying lung cancer which is expected to influence QoL; 5. Expected survival of three months or less; 6. ECOG Performance status of 3 or 4 (see Appendix D); 7. Multiple CNS metastasis or a single CNS lesion that does not demonstrate radiographic stability (Screening CT of head required only if symptomatic, no radiographic follow-up of single resected lesions required); 8. Blood transfusions within the last 14 days; 9. Previous use of erythropoietin; 10. Anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or gastrointestinal bleeding); 11. Evidence of untreated folate or vitamin B12 deficiency; 12. History of uncontrolled hypertension or diastolic blood pressure greater than 100 mm Hg; 13. History of seizure disorder; 14. Known hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug; 15. Pregnancy, lactation or parturition within the previous 30 days; 16. Unwillingness or inability to complete the required QoL questionnaires; 17. Mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of questionnaires; 18. Geographically inaccessible for treatment or follow-up evaluations; 19. Currently enrolled in an ongoing therapeutic study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in anemia and fatigue related QoL at 12 weeks following randomization | 12 weeks following randomization |
Secondary
| Measure | Time frame |
|---|---|
| Overall QoL and domain-specific QoL scores | 16 weeks following randomization |
| hemoglobin and hematocrit levels | 6 months from randomization |
| number of transfusions | 6 months from randomization |
Countries
Canada
Outcome results
None listed